Dexpass FilmCoated Tablet 50 Mg

Dexpass is a medication containing Dexketoprofen Trometamol as its active ingredient, formulated as 50 mg film-coated tablets. This pharmaceutical product belongs to the non-steroidal anti-inflammatory drug (NSAID) class within the arylpropionic acid group. Specifically developed for pain management, Dexpass offers rapid onset of action with notable analgesic, anti-inflammatory, and antipyretic properties.

The following comprehensive analysis details the pharmacological characteristics, therapeutic applications, administration guidelines, and safety considerations for Dexpass Film Coated Tablet 50 Mg.

Pharmacological Properties

Chemical Composition

Dexpass 50 mg contains Dexketoprofen Trometamol as its primary active ingredient. Dexketoprofen represents the dextrorotatory enantiomer of ketoprofen, demonstrating greater potency than the racemic mixture.

The trometamol salt form enhances the compound’s solubility, facilitating more rapid absorption following oral administration. The film coating surrounding the tablet core serves to protect the active ingredient while easing swallowing and masking potential bitter taste. Each tablet delivers 50 mg of Dexketoprofen Trometamol, equivalent to 36.9 mg of Dexketoprofen.

Mechanism of Action

Dexketoprofen Trometamol functions primarily through inhibition of prostaglandin synthesis by blocking the cyclooxygenase (COX) pathway. This mechanism targets both COX-1 and COX-2 isoenzymes, although it demonstrates greater selectivity for COX-1.

By preventing the conversion of arachidonic acid to prostaglandins, Dexketoprofen reduces inflammation, pain, and fever at both peripheral and central sites. The trometamol salt formulation contributes to its rapid absorption, allowing for quicker onset of analgesic action compared to conventional NSAIDs. This rapid action makes it particularly valuable for acute pain management scenarios where prompt relief is essential.

Pharmacokinetics

Following oral administration, Dexpass demonstrates favorable pharmacokinetic properties. Absorption occurs rapidly in the gastrointestinal tract, with peak plasma concentrations achieved within 30 minutes to 1 hour after ingestion. Food intake may delay absorption time but does not significantly affect the extent of absorption. The bioavailability of Dexketoprofen from Dexpass tablets exceeds 80%, with extensive plasma protein binding (approximately 99%).

The drug undergoes hepatic metabolism primarily through glucuronidation and is mainly excreted via the kidneys. The elimination half-life ranges between 1.65 to 4 hours, allowing for convenient dosing intervals.

Clinical Applications

Indications

Dexpass Film Coated Tablet 50 Mg is primarily indicated for the symptomatic treatment of acute pain of moderate to severe intensity. The clinical applications encompass a broad spectrum of painful conditions, including:

• Musculoskeletal pain (including low back pain and joint pain)

• Post-traumatic pain (sprains, strains, contusions)

• Postoperative pain

• Dental pain following extraction or surgical procedures

• Primary dysmenorrhea (menstrual pain)

• Renal colic

• Acute migraine attacks with or without aura

The versatility of Dexpass makes it a valuable therapeutic option across various clinical scenarios requiring rapid and effective pain management.

Therapeutic Benefits

The therapeutic advantages of Dexpass extend beyond simple pain relief. Clinical studies have demonstrated that Dexketoprofen Trometamol provides faster onset of analgesic action compared to many traditional NSAIDs.

Patients typically experience meaningful pain relief within 30 minutes of administration, with effects persisting for approximately 4-6 hours. Additionally, the potent anti-inflammatory properties make it effective for conditions involving inflammation-mediated pain. The antipyretic effect further enhances its utility in managing febrile conditions accompanying painful disorders. These combined properties establish Dexpass as a comprehensive option for acute pain management.

Administration Guidelines

Recommended Dosage

The standard recommended dosage of Dexpass 50 mg tablets for adults is typically one tablet (50 mg) every 8 hours, with a maximum daily dose not exceeding three tablets (150 mg). For elderly patients or those with compromised renal or hepatic function, dose adjustments may be necessary, often starting with one tablet (50 mg) every 12 hours with careful monitoring for adverse effects.

The treatment duration should generally be limited to the acute phase of the condition, typically not exceeding 5 consecutive days. Extended treatment periods should occur only under close medical supervision and after careful assessment of the benefit-risk ratio for the individual patient.

Method of Administration

Dexpass Film Coated Tablets should be taken orally with a sufficient quantity of water (minimum 100 mL). Administration with food is recommended to minimize the risk of gastrointestinal adverse effects, although this may slightly delay the onset of action.

The tablets should be swallowed whole and not crushed, chewed, or broken, as this could alter the release properties and potentially increase adverse effects. For optimal analgesic effect, consistent timing of doses is advised. When taken for postprandial pain, the administration should occur at least 30 minutes before meals to prevent delayed absorption.

Safety Profile

Contraindications

Dexpass is contraindicated in numerous clinical situations to ensure patient safety. Absolute contraindications include:

• Hypersensitivity to Dexketoprofen, other NSAIDs, or any excipients in the formulation

• History of asthma, bronchospasm, acute rhinitis, nasal polyps, urticaria, or angioedema precipitated by aspirin or other NSAIDs

• Active peptic ulceration or history of recurrent peptic ulceration/hemorrhage

• Gastrointestinal bleeding or perforation related to previous NSAID therapy

• Severe heart failure (NYHA Class IV)

• Moderate to severe renal dysfunction (creatinine clearance <50 mL/min)

• Severe hepatic impairment (Child-Pugh score 10-15)

• Established cerebrovascular or other active bleeding

• Blood coagulation disorders

• Third trimester of pregnancy and during lactation

Precautions and Warnings

Several important precautions warrant consideration when prescribing Dexpass. Healthcare providers should exercise caution in patients with:

• History of inflammatory bowel disease (Crohn’s disease or ulcerative colitis)

• Mild to moderate heart failure, hypertension, or edema

• Mild to moderate renal impairment (monitoring of renal function is advised)

• Mild to moderate hepatic dysfunction

• Elderly patients (increased risk of adverse effects)

• Dehydration (should be corrected before initiating therapy)

• Systemic lupus erythematosus or mixed connective tissue disease (increased risk of aseptic meningitis)

• First or second trimester of pregnancy (use only if clearly necessary)

Additionally, all patients should be monitored for signs of gastrointestinal bleeding and cardiovascular events, particularly during the initial treatment phase.

Adverse Effects

Dexpass, like other NSAIDs, is associated with a range of potential adverse effects. Gastrointestinal disturbances represent the most commonly reported issues, including nausea, vomiting, abdominal pain, dyspepsia, diarrhea, and constipation. More serious gastrointestinal complications such as ulceration, bleeding, and perforation may occur, particularly with prolonged use or in high-risk patients.

Cardiovascular effects, although less common, include hypertension, peripheral edema, and in rare cases, heart failure exacerbation. Neurological adverse effects encompass headache, dizziness, somnolence, and rarely, aseptic meningitis. Dermatological reactions ranging from rash to severe cutaneous adverse reactions have been documented in rare instances. Renal effects include reduced renal function, particularly in susceptible individuals with pre-existing renal impairment.

Drug Interactions

Dexpass demonstrates significant potential for interactions with various medications, necessitating careful consideration when prescribed concurrently. Concomitant use with other NSAIDs, including selective COX-2 inhibitors, increases the risk of gastrointestinal ulceration and bleeding. Anticoagulants and antiplatelet agents (including low-dose aspirin) can enhance bleeding risk when combined with Dexpass.

Corticosteroids may also increase gastrointestinal adverse effect risk. Lithium and methotrexate plasma levels may be elevated by Dexketoprofen, potentially leading to toxicity. Antihypertensive effects of ACE inhibitors, angiotensin II antagonists, and diuretics can be diminished. Pentoxifylline may increase bleeding risk, while cyclosporine and tacrolimus can enhance nephrotoxicity when administered concomitantly. These potential interactions highlight the importance of comprehensive medication review before initiating Dexpass therapy.

Special Populations

Elderly Patients

Elderly patients require special consideration when prescribed Dexpass due to their increased susceptibility to NSAID-related adverse effects. Age-related reductions in renal function, elevated risk of gastrointestinal complications, and higher likelihood of cardiovascular comorbidities necessitate cautious dosing. The recommended starting dosage for elderly patients is often reduced to 50 mg every 12 hours, with close monitoring for adverse effects.

Treatment duration should be minimized, and regular assessment of renal function is advisable. The benefit-risk profile should be carefully evaluated before initiating therapy in this vulnerable population.

Patients with Renal Impairment

Renal function significantly influences Dexketoprofen elimination, making dosage adjustments necessary for patients with impaired kidney function. For mild renal impairment (creatinine clearance 50-80 mL/min), the initial dose should be reduced to 50 mg daily with careful monitoring and gradual titration if needed. Moderate to severe renal impairment (creatinine clearance <50 mL/min) represents a contraindication for Dexpass.

Regular monitoring of renal function parameters is essential for all patients with any degree of renal compromise. The potential for further deterioration of renal function warrants particular vigilance in these patients.

Patients with Hepatic Impairment

Liver function affects the metabolism and clearance of Dexketoprofen, necessitating careful consideration in patients with hepatic impairment. For mild to moderate hepatic dysfunction (Child-Pugh score 5-9), reduced initial dosing of 50 mg daily is recommended with careful monitoring for adverse effects.

Severe hepatic impairment (Child-Pugh score 10-15) constitutes an absolute contraindication to Dexpass use due to the heightened risk of toxicity. Liver function tests should be regularly monitored during treatment in patients with any degree of hepatic compromise. Treatment duration should be minimized to reduce the potential for hepatotoxicity.

Pregnancy and Lactation

Dexpass administration during pregnancy requires careful consideration of benefit versus risk. During the first and second trimesters, use should be avoided unless clearly necessary, and if prescribed, the lowest effective dose for the shortest duration should be employed. Dexpass is absolutely contraindicated during the third trimester due to risks of premature closure of the ductus arteriosus, delayed labor, and increased bleeding complications.

Regarding lactation, Dexketoprofen can be excreted in breast milk, potentially affecting the nursing infant. Consequently, Dexpass is contraindicated during breastfeeding. Women of childbearing potential should be advised about these considerations before initiating treatment.

Storage and Handling

Proper storage and handling of Dexpass Film Coated Tablets are essential to maintain product integrity and efficacy. The tablets should be stored at room temperature (15-30°C) in a dry place, protected from light in their original packaging. Excessive heat and moisture exposure should be avoided as this may compromise the film coating and accelerate degradation of the active ingredient.

The blister packaging should remain intact until immediately before administration. Patients should be instructed to check the expiration date before use and never use expired medication. Any unused or expired tablets should be properly disposed of according to local pharmaceutical waste regulations rather than discarded in household waste or wastewater to prevent environmental contamination.

Dexpass Film-Coated Tablet 50 Mg: Key Information Table